Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage
Shipping and logistics companies are tapping into the growing market of healthcare as cold chain and temperature-controlled facilities become more crucial.
As specialized medications like GLP-1s surge in demand, logistics firms like UPS and FedEx are stepping up their approaches to more efficiently transport and store these pharmaceuticals. Refrigerated storage is essential for most injectable GLP-1 drugs, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound.
The COVID-19 pandemic amplified the significance of healthcare logistics, particularly the shipping of temperature-controlled vaccines. Consequently, logistics companies are capitalizing on this trend by investing heavily in temperature-controlled facilities. UPS recently announced a $48 million investment, recognizing a growing demand for critical treatments.
The market for temperature-sensitive biologics is projected to grow at an 8.3% CAGR through 2033, reaching an estimated $39.1 billion. Obesity and diabetes medications are also gaining traction, with 11% of Americans now taking GLP-1 drugs for weight loss, up from 3% in 2024. However, improper storage and shipping can compromise the drugs' efficacy, prompting the FDA to caution against using GLP-1 drugs that arrive warm or inadequately refrigerated.
Other temperature-sensitive biologics, such as vaccines, insulin, and antibiotics, also necessitate specialized shipment methods. Logistics companies must ensure proper storage and movement throughout the supply chain to maintain the drugs' integrity. UPS and FedEx have both expanded their capabilities to meet the escalating demand for healthcare logistics.
UPS CEO Carol Tomé highlighted that the company's global healthcare portfolio has grown annually since 2021, generating its first $3 billion healthcare revenue quarter in Q1 2024. UPS President John Bolla emphasized the company's focus on supporting specialized therapies and care delivered outside traditional healthcare settings.
FedEx, for its part, launched a life sciences division earlier this year to support the movement of pharmaceuticals and other healthcare products. The company's Chief Customer Officer, Brie Carere, noted that healthcare transportation revenue in fiscal year 2026 reached nearly $10 billion. FedEx's specialized technology, including its machine learning engine, allows it to predict product movement and tailor treatment based on each product's unique requirements.
C.H. Robinson, another logistics firm, reported surpassing $1 billion in revenue from healthcare logistics in the past year, largely driven by the growth in GLP-1 drugs. The company's vice president of North American surface transportation, Ronnie Davis, stressed the importance of end-to-end connectivity and a robust network infrastructure to effectively serve healthcare customers.
As the supply chain for medications becomes more intricate, the stress on cold chain capabilities grows, with the available resources for refrigerated storage becoming increasingly constrained.
Written by urgent.news from CNBC's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
